(DVA) DaVita HealthCare Partners - Ratings and Ratios

DaVita Inc. (NYSE:DVA) is a leading provider of kidney dialysis services for patients with chronic kidney failure and end-stage renal disease (ESRD) in the United States. The company operates a network of outpatient dialysis centers, offering hemodialysis, peritoneal dialysis, and home-based dialysis services. Its clinical laboratories provide routine and specialized tests for ESRD patients, while its management and administrative services support the operational efficiency of dialysis centers. DaVita also offers integrated care and disease management programs, clinical research initiatives, physician services, and comprehensive kidney care solutions. Additionally, the company provides inpatient dialysis services, laboratory services, and transplant software solutions. DaVita Inc., rebranded from DaVita HealthCare Partners Inc. in September 2016, was founded in 1994 and is headquartered in Denver, Colorado.

As of the latest data, DaVita Inc. has a market capitalization of $12.268 billion USD, with a price-to-earnings (P/E) ratio of 14.24 and a forward P/E of 13.87. The companys price-to-book (P/B) ratio is 100.96, and its price-to-sales (P/S) ratio is 0.96. DaVitas return on equity (RoE) stands at 773.06, indicating strong profitability relative to shareholder equity. Technically, the stock is trading at $134.97, below its 20-day, 50-day, and 200-day simple moving averages (SMA) of 148.33, 149.56, and 153.55, respectively. The average true range (ATR) is 5.12, reflecting moderate volatility.